URGN FY 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$64M+34.0% YoY

Gross Profit

$57M88.1% margin

Operating Income

-$79M-122.8% margin

Net Income

-$110M-170.6% margin

EPS (Diluted)

$-4.79

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$88M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$136M

Total Liabilities

$225M

Stockholders' Equity

-$89M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$48M	+34.0%
Gross Profit	$57M	$43M	+32.2%
Operating Income	-$79M	-$92M	+14.4%
Net Income	-$110M	-$111M	+0.9%